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Summary
Background Preoperative (neoadjuvant) chemotherapy and radiotherapy are more eﬀ ective than similar postoperative 
treatment for oesophageal, gastric, and rectal cancers, perhaps because of more eﬀ ective micrometastasis eradication 
and reduced risk of incomplete excision and tumour cell shedding during surgery. The FOxTROT trial aims to 
investigate the feasibility, safety, and eﬃ  cacy of preoperative chemotherapy for colon cancer.
Methods In the pilot stage of this randomised controlled trial, 150 patients with radiologically staged locally advanced 
(T3 with ≥5 mm invasion beyond the muscularis propria or T4) tumours from 35 UK centres were randomly 
assigned (2:1) to preoperative (three cycles of OxMdG [oxaliplatin 85 mg/m², l-folinic acid 175 mg, ﬂ uorouracil 
400 mg/m² bolus, then 2400 mg/m² by 46 h infusion] repeated at 2-weekly intervals followed by surgery and a 
further nine cycles of OxMdG) or standard postoperative chemotherapy (12 cycles of OxMdG). Patients with KRAS 
wild-type tumours were randomly assigned (1:1) to receive panitumumab (6 mg/kg; every 2 weeks with the ﬁ rst 
6 weeks of chemotherapy) or not. Treatment allocation was through a central randomisation service using a 
minimised randomisation procedure including age, radiological T and N stage, site of tumour, and presence of 
defunctioning colostomy as stratiﬁ cation variables. Primary outcome measures of the pilot phase were feasibility, 
safety, and tolerance of preoperative therapy, and accuracy of radiological staging. Analysis was by intention to treat. 
This trial is registered, number ISRCTN 87163246.
Findings 96% (95 of 99) of patients started and 89% (85 of 95) completed preoperative chemotherapy with grade 3–4 
gastrointestinal toxicity in 7% (seven of 94) of patients. All 99 tumours in the preoperative group were resected, with 
no signiﬁ cant diﬀ erences in postoperative morbidity between the preoperative and control groups: 14% (14 of 99) 
versus 12% (six of 51) had complications prolonging hospital stay (p=0·81). 98% (50 of 51) of postoperative 
chemotherapy patients had T3 or more advanced tumours conﬁ rmed at post-resection pathology compared with 91% 
(90 of 99) of patients following preoperative chemotherapy (p=0·10). Preoperative therapy resulted in signiﬁ cant 
downstaging of TNM5 compared with the postoperative group (p=0·04), including two pathological complete 
responses, apical node involvement (1% [one of 98] vs 20% [ten of 50], p<0·0001), resection margin involvement (4% 
[ four of 99] vs 20% [ten of 50], p=0·002), and blinded centrally scored tumour regression grading: 31% (29 of 94) vs 2% 
(one of 46) moderate or greater regression (p=0·0001).
Interpretation Preoperative chemotherapy for radiologically staged, locally advanced operable primary colon cancer is 
feasible with acceptable toxicity and perioperative morbidity. Proceeding to the phase 3 trial, to establish whether the 
encouraging pathological responses seen with preoperative therapy translates into improved long-term oncological 
outcome, is appropriate.
Funding Cancer Research UK.
Introduction
Preoperative (neoadjuvant) chemotherapy and radio-
therapy are substantially more eﬀ ective than similar 
postoperative therapy in oesophageal, gastric, and rectal 
cancer.1–3 Earlier treatment might be more eﬀ ective at 
eradicating micrometastatic disease than the same 
treatment 3 months later,4,5 the typical period between 
diagnosis and starting postoperative chemotherapy, 
particularly because surgery increases growth factor 
activity in the early postoperative period, promoting 
more rapid tumour progression.6–8
Shrinking of tumours before surgery might also reduce 
the frequency of tumour cell shedding during surgery9 
and of incomplete excision.2,10 Surgical resection margin 
involvement correlates strongly with locoregional 
recurrence,11 which can have a more aggressive pheno-
type12 and respond poorly to systemic therapy.13 Other 
potential advantages of preoperative therapy are to make 
minimum access surgery practicable, enabling earlier 
return to normal activity,14 and better tolerability than 
similar treatment after major surgery, hence allowing 
increased dose intensity.3 Assessment of response to 
preoperative chemotherapy might also be useful in 
guiding postoperative drug selection.
Although an attractive concept, preoperative chemo-
therapy has not, until now, been assessed in operable 
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colon cancer because of concerns that, if tumour growth 
occurred during the preoperative treatment phase, this 
could result in bowel obstruction necessitating 
emergency surgery, an outcome associated with high 
morbidity and mortality. Another concern is that 
inaccurate radiological tumour staging might result in 
inappropriate chemotherapy for low-risk patients. 
However, with more eﬀ ective regimens and advances in 
radiological staging,15 preoperative chemotherapy has 
become a promising option.
Response rates higher than 50% are consistently 
achieved in metastatic colorectal cancer with chemo-
therapy regimens combining ﬂ uoropyrimidines with 
irinotecan or oxaliplatin,16,17 and even higher responses 
can be achieved—in KRAS wild-type tumours—by adding 
EGFR-targeted monoclonal antibodies, panitumumab or 
cetuximab, to combination chemotherapy.17–30 The pro-
portional improvements in tumour response rate with 
anti-EGFR monoclonal antibodies depend on treatment 
stage, but the absolute improvements are similar: 15% 
(15% vs 0·4%, p<0·0001)18–20 when used as single agents 
for patients who had not responded to standard 
chemotherapy, 18% (25% vs 7%, p<0·0001)21–23 when 
added to second-line irinotecan-based chemotherapy, and 
9% (57% vs 48%, p<0·0001)24–30 when added to ﬁ rst-line 
chemo therapy (appendix). Eﬃ  cacy of ﬁ rst-line anti-EGFR 
monoclonal antibodies appears similar when background 
chemotherapy is ﬂ uorouracil or capecitabine-based and 
with oxaliplatin or irinotecan.31 Thus, although EGFR-
targeted therapies are ineﬀ ective, and might be harmful, 
in KRAS mutant tumours,20,21,24,27 response of metastatic 
KRAS wild-type colonic tumours is clearly increased by 
adding anti-EGFR therapies to chemotherapy, suggest-
ing potential beneﬁ ts as an adjuvant to preoperative 
oxaliplatin-based chemotherapy in operable disease.
Moreover, tumours suitable for preoperative chemo-
therapy can now be accurately identiﬁ ed with a CT risk 
stratiﬁ cation algorithm based on the depth of tumour 
invasion beyond the muscularis propria.15 High-risk 
patients (stage T4 or T3 with ≥5 mm tumour invasion 
beyond muscularis propria) have a 53% 3-year recur-
rence-free survival compared with 87% for the good 
(T1/T2) or intermediate (T3 and <5 mm tumour invasion 
beyond muscularis propria) prognostic groups.
The FOxTROT (Fluoropyrimidine Oxaliplatin and 
Targeted Receptor Pre-Operative Therapy) trial was 
designed to assess whether 6 weeks of an eﬀ ective 
combination chemotherapy regimen given preoperatively 
to patients with radiologically staged, locally advanced, 
but potentially resectable colon cancer improves 
disease-free survival, and whether the addition of an 
EGFR-targeted monoclonal antibody, panitumumab, to 
preoperative chemotherapy increases tumour shrinkage 
for patients with wild-type KRAS tumours. A feasibility 
phase, reported here, was incorporated to assess patient 
selection and recruitment, safety, and tumour response 
to preoperative treatment.
Methods 
Patients
Eligible patients were 18 years or older with locally 
advanced (T4 or T3 with extramural depth ≥5 mm) 
adenocarcinoma of the colon, with staging determined 
preoperatively by either spiral or multidetector CT15 and 
for whom a 24-week course of oxaliplatin and ﬂ uoro-
pyrimidine-based adjuvant chemotherapy would be 
judged appropriate. Patients were required to have 
adequate blood counts—haemoglobin greater than 
100 g/L after trans fusion and before surgery and 
chemotherapy, greater than 3·0×10⁹ white blood cells 
per L, and greater than 100×10⁹ platelets per L; adequate 
renal biochemistry with a glomerular ﬁ ltration rate of 
greater than 50 mL per minute as calculated by the 
Wright or Cockroft formula or EDTA clearance of greater 
than 70 mL per minute; adequate hepatobiliary function 
with bilirubin less than 25 μmol per L; and serum 
magnesium levels within the normal range at trial entry. 
Written consent was obtained from patients, and ethics 
approval was obtained from the West Glasgow 
multicentre ethics committee (Glasgow, UK). The 
protocol is available online.
Randomisation and masking
Eligible patients were randomly assigned, in a 2:1 ratio, 
between preoperative plus postoperative and post-
operative chemotherapy. Patients were also randomly 
assigned, in a 1:1 ratio, to receive panitumumab with the 
ﬁ rst 6 weeks of chemotherapy or not (ﬁ gure 1). Patients 
were allocated to a treatment group by a telephone or 
web-based central randomisation service at the Univer-
sity of Birmingham Clinical Trials Unit (Birmingham, 
UK). A computerised minimised ran domisation pro-
cedure was used to ensure a good balance between 
groups for age (<50, 50–59, 60–69, ≥70 years), radiological 
T-stage (T3, T4), radiological nodal status (Nx, N0, N1, 
See Online for appendix
For protocol see http://www.
birmingham.ac.uk/FOxTROT
Figure 1: FOxTROT trial schema
OxMdG=modiﬁ ed de Gramont chemotherapy. Pan=panitumumab. CT=computed tomography. R=randomisation.
Operable colon 
cancer (T4 or 
high-risk T3 
tumour by CT; 
ﬁt for surgery and 
chemotherapy) 
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×
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N2), site of primary tumour, and defunctioning colos-
tomy (yes, no). Treatment was open-label.
Soon after the start of FOxTROT, the poor eﬀ ectiveness 
of EGFR monoclonal antibodies in tumours harbouring 
a KRAS mutation18–20 mandated introduction of pre-
operative KRAS testing of diagnostic biopsy samples, 
with only KRAS wild-type tumours eligible for the 
panitumumab randomisation. A two-stage consent and 
randomisation procedure was introduced. Patients were 
ﬁ rst invited to consent to molecular testing, then to 
randomisation for either preoperative plus postoperative 
chemotherapy or postoperative chemotherapy only. Only 
patients whose tumours tested as KRAS wild-type were 
entered in the panitumumab randomisation.
Procedures
Chemotherapy was the standard UK modiﬁ ed de 
Gramont (OxMdG) regimen,32 consisting of cycles of 
oxaliplatin at 85 mg/m² combined with l-folinic acid 
175 mg/m2 plus ﬂ uorouracil 400 mg/m² by intravenous 
bolus, followed by a 46 h infusion of 2400 mg/m² through 
an indwelling line, repeated at 2-weekly intervals. 
Capecitabine could not be substituted for ﬂ uorouracil 
and folinic acid in this pilot study because of higher 
toxicity when combined with panitumumab.17 Dose 
reductions and delays of up to 4 weeks were allowed for 
reversible toxicity. Preoperative chemotherapy duration 
was only 6 weeks (three cycles of OxMdG) to minimise 
the risk of progression of chemoresistant tumours 
(15–20% of advanced metastatic colon cancers progress 
during 12 weeks of similar combination chemo-
therapy).16,17,24,26 Sur gery with curative intent was under-
taken at least 3 weeks after completing preoperative 
therapy, to reduce perioperative morbidity,2 followed by a 
further 18 weeks (nine cycles) of OxMdG. CT scans were 
repeated before surgery in the pre operative group. For 
the patients who were not assigned to receive preoperative 
chemotherapy, postoperative chemotherapy duration was 
24 weeks (12 cycles) of OxMdG. If allocated, panitumumab 
(6 mg/kg) was given by intravenous infusion at 2-weekly 
intervals during the ﬁ rst 6 weeks of chemotherapy 
(preoperative or postoperative).
The primary outcomes of the pilot phase were feasibility, 
safety, tolerance of preoperative therapy, and the accuracy 
of radiological staging. Other key outcomes were 
completion of planned surgery, peri operative morbidity, 
timely completion of preoperative KRAS testing, and 
downstaging of the resected tumour as measured by 
histopathological tumour diameter and stage. Tumour 
staging was standardised across centres, with training 
provided for participating specialist gastro intestinal 
radiologists and histopathologists. Pathological reports 
and tumour blocks were collected centrally with tumour 
regression grades scored masked to treatment allocation.
Statistical analysis
The FOxTROT study aims to randomly assign at least 
1050 patients to detect a 25% proportional reduction 
(roughly 8% absolute diﬀ erence) in recurrence at 2 years 
(eg, 32% reduced to 24%) with 80% power at p<0·05. 
The prespeciﬁ ed sample size of 150 for the pilot phase 
was chosen pragmatically as a suﬃ  cient number to 
assess the potential rate of recruitment and any large 
diﬀ erences in other primary outcomes. An independent 
steering committee advised whether to continue to the 
full study. Comparisons of preoperative versus post-
operative chemotherapy were by intention to treat 
including all patients randomly assigned to treatment 
groups, ignoring panitumumab allocation, and using 
Preoperative plus 
postoperative 
chemotherapy (n=99)
Postoperative 
chemotherapy 
only (n=51)
Age (years)
Median (IQR) 64 (59–68) 65 (56–69)
Range 31–82 38–78
Age group (years)
<50 9 (9%) 4 (8%)
50–59 16 (16%) 10 (20%)
60–69 50 (51%) 26 (51%)
≥70 24 (24%) 11 (22%)
Sex
Male 65 (66%) 32 (63%)
Female 34 (34%) 19 (37%)
Colonic obstruction 3/99 (3%) 1/51 (2%) 
WHO performance status
0 67 (68%) 34 (67%)
1 30 (30%) 17 (33%)
2 2 (2%) 0
Location
Caecum 23 (23%) 11 (22%)
Ascending colon 18 (18%) 11 (22%)
Hepatic ﬂ exure 5 (5%) 3 (6%)
Transverse colon 7 (7%) 3 (6%)
Splenic ﬂ exure 3 (3%) 1 (2%)
Descending colon 3 (3%) 3 (6%)
Sigmoid 32 (32%) 15 (29%)
Rectosigmoid 8 (8%) 4 (8%)
Radiological T-stage
T3 69 (70%) 35 (69%)
T4 30 (30%) 16 (31%)
Radiological N-stage
Nx 3 (3%) 1 (2%)
N0 23 (23%) 12 (24%)
N1 44 (45%) 22 (43%)
N2 29 (29%) 16 (31%)
Extramural vascular invasion 57/98 (58%)* 31/51 (61%)
Mean (SD) 12·9 (8·8) 15·5 (9·9)
Range 1–50 5–50
One radiology form had missing extramural vascular invasion data.
Table 1: Patient characteristics at baseline radiology
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t tests to compare continuous variables, Mantel-
Haenszel tests of association for ordinal variables, and 
SAS 9.2 statistical software.
The trial is registered, number ISRCTN 87163246.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors of the writing 
committee had full access to all the data in the study 
and had joint ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between May 15, 2008, and Sept 21, 2010, 150 patients 
from 35 UK centres were randomly assigned to receive 
either preoperative plus postoperative chemotherapy 
(n=99) or standard postoperative chemotherapy alone 
(n=51). Radiologically classiﬁ ed tumour characteristics 
were similarly distributed across treatment groups 
(table 1). Patient screening logs suggested that the main 
reason for clinicians not entering radiologically eligible 
patients was unsuitability for combination chemotherapy 
because of age or frailty. Patients were also excluded 
because of uncertainty about eligibility on CT staging, 
principally on whether depth of invasion beyond the 
muscularis propria was 5 mm or more. Premature 
scheduling of the operation date was also a common 
exclusion reason before the multidisciplinary teams and 
individual clinicians adapted to the new care pathway.
138 of the 150 patients were eligible for KRAS testing to 
establish eligibility for the panitumumab random isation: 
two were entered before KRAS testing was introduced, 
six were entered while the panitumumab randomisation 
was suspended, and four were from centres not taking 
part in the panitumumab random isation (appendix). 
Biopsy samples were obtained for 98% (135 of 138) of 
these patients and 96% (130 of 135) were successfully 
tested. 72% (95 of 132 with known KRAS status, including 
the two patients retrospectively tested) were KRAS wild-
type of whom 90 were randomly assigned to either 
panitumumab or control, with four KRAS wild-type 
results arriving too late for panitumumab randomisation 
and one patient declining randomisation. 46 (31% of all 
150 patients) were allocated panitumumab. The median 
time from consent to KRAS test result and panitumumab 
randomisation was 9 days (IQR 7–12).
Of 99 patients allocated preoperative chemotherapy, 
95 (96%) started treatment as planned with one pro-
ceeding directly to surgery after diagnosis of a localised 
perforation and three because of patient or clinician’s 
choice (ﬁ gure 2). The mean delay from randomisation to 
start of chemotherapy was 13 (SD 6) days. 89% (85 of 95) 
of patients starting preoperative treatment completed the 
6-week course with nine stopping early because of toxicity 
and one withdrawing to oﬀ -trial bevacizumab treatment. 
All 99 patients underwent resectional surgery with a mean 
time to surgery from start of chemotherapy of 61 (SD 15) 
days. 83% (82 of 99) continued with post operative OxMdG 
chemotherapy. 15 patients had no postoperative chemo-
therapy; ﬁ ve patients (including three who had no 
preoperative chemotherapy) did not have postoperative 
chemotherapy because of low-risk pathology, ﬁ ve because 
of previous adverse events (four because of toxicity of 
preoperative chemotherapy, one because of surgical 
morbidity), three refused, one had metastatic disease, and 
one died in the postoperative period. Additionally, two had 
oﬀ -protocol treatment (one patient had a diﬀ erent 
chemotherapy regimen, and one was treated with 
bevacizumab). 96% (79 of 82) of those starting completed 
the ﬁ rst 6 weeks (three stopped because of toxicity) and 
Figure 2: FOxTROT patient pathway
99 allocated preoperative and postoperative 
       chemotherapy 
51 allocated postoperative chemotherapy only
150 randomised in pilot study
1 perforation
3 clinician or patient choice
1 died before surgery,
2 not resected because of 
    advanced disease
95 started preoperative chemotherapy
85 completed preoperative chemotherapy
      (3 cycles)
48 underwent surgery
8 had no postoperative 
chemotherapy
99 underwent surgery 40 started postoperative chemotherapy 
38 completed ﬁrst three cycles (1 died, 1 stopped 
       after chest pain)
15 had no postoperative 
chemotherapy
  2 had oﬀ-protocol treatment
82 started postoperative chemotherapy
79 completed ﬁrst three cycles (3 stopped due 
      to toxicity)
38 started second three cycles of postoperative 
chemotherapy
36 completed (2 stopped due to toxicity)
1 stopped due to toxicity
1 missing data
77 started second three cycles of postoperative 
chemotherapy
76 completed (1 stopped, reason unknown)
34 started third three cycles of postoperative 
chemotherapy
33 completed (1 stopped due to toxicity)
1 possible cerebrovascular accident
1 unknown
1 missing data
74 started ﬁnal three cycles of postoperative 
chemotherapy
67 completed (4 stopped due to toxicity, 
      1 venous access problems, 2 unknown)
32 started ﬁnal three cycles of postoperative 
chemotherapy
29 completed (2 stopped due to toxicity, 
       1 venous access problems)
1 possible liver metastasis
1 missing data
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82% (67 of 82) completed all 18 weeks of postoperative 
treatment. Toxicity was the most common reason for 
stopping treatment, with nine patients stopping at some 
point during postoperative chemotherapy (four during or 
after the ﬁ rst three cycles of postoperative chemotherapy, 
one after the second three cycles, and four during or after 
the ﬁ nal three cycles).
Of 51 patients allocated postoperative chemotherapy, 
94% (48 of 51) had resectional surgery with one dying 
beforehand and two who were not resected because of 
inoperable peritoneal spread detected at surgery (ﬁ gure 2). 
78% (40 of 51) started postoperative chemo therapy with 
11 not having postoperative chemo therapy because of low-
risk pathology (seven) or dying before hand (four). 95% 
(38 of 40) of those starting completed the ﬁ rst 6 weeks and 
72% (29 of 40) completed all 24 weeks of chemotherapy. 
Toxicity caused six patients to discontinue chemotherapy.
Thus, a higher proportion of patients started pre-
operative than postoperative chemotherapy (96% [95 of 
99] vs 78% [40 of 51]; p=0·001), and chemotherapy 
completion rates were also higher in the preoperative 
therapy group with 68% (67 of 99) of those allocated pre 
plus postoperative chemotherapy completing 24 weeks of 
treatment compared with 57% (29 of 51) of postoperative 
chemotherapy patients (p=0·19).
Accuracy of radiological staging was assessed by 
pathological examination of resected tumours from the 
postoperative chemotherapy only group. 86% (43 of 50 
[including two that were unresected]) of tumours had 
adverse features (inoperable tumour, positive lymph 
nodes, extramural vascular invasion [EMVI], or depth of 
invasion ≥5 mm) on pathological examination, indicative 
of a greater than 50% recurrence risk at 3 years. Radiology 
accurately identiﬁ ed invasion of the muscularis propria, 
with only 2% (one of 51) of patients in the postoperative 
group having a pathological T2 (pT2) tumour; a further 
12% (six of 51) had pT3 tumours without additional risk 
factors. Radiology was less accurate in discriminating 
between T3 and T4 stage, with 47% (eight of 17) of pT4 
tumours also T4 on radiological assessment and 50% 
(8 of 16) of those T4 on radiology were pT3 on pathological 
assessment. Radiological assessment was more sensitive 
in detecting nodal spread with 83% (20 of 24) of patho-
logical node-positive patients also node-positive on radio-
logical assessment. However, speciﬁ city was low with 
radio logical staging tending to overestimate tumour 
spread: 44% (16 of 36) of those node-positive on radiology 
were node-negative on pathological assessment. Simi-
larly, 52% (14 of 27) of those with extramural vascular 
invasion on radiology were EMVI-negative on patho-
logical assessment.
One patient in each group needed acute surgery 
because of incipient obstruction, with both proceeding to 
resectional surgery. No signiﬁ cant diﬀ erences were seen 
in complication rates (table 2) or median time to hospital 
discharge (preoperative plus postoperative chemotherapy 
group: 7 days, IQR 5–10; postoperative only: 6 days, 3–8; 
p=0·18) although there was a greater proportion of wound 
infections in the pre operative group (table 2). The 
proportions of patients with complications that prolonged 
hospital stay, or had procedures that resulted in a stoma 
or required further adominal surgery for anastomotic 
complications, were much the same for the two groups 
(table 2). The median delay after surgery to starting 
chemotherapy was 47 days (IQR 40–55) for patients 
allocated preoperative chemotherapy and 53 days (44–57) 
for patients allocated postoperative chemotherapy.
Of those receiving chemotherapy, toxicity was similar 
between groups in the ﬁ rst 6 weeks and in subsequent 
treatment (appendix). 34% (32 of 94) of preoperative and 
31% (12 of 39) of postoperative chemotherapy patients had 
grade 3 or worse toxicity in their ﬁ rst 6 weeks of 
chemotherapy (p=0·72). 7% (seven of 94) of preoperative 
and 10% (four of 39) of postoperative chemotherapy 
patients had grade 3 or worse gastrointestinal toxicity; 11% 
(nine of 85) versus 21% (eight of 38) required dose 
reductions (p=0·12) and 11% (ten of 95) versus 5% (two of 
40) did not complete their ﬁ rst 6 weeks of chemotherapy 
(p=0·31). Only one patient had surgery delayed, for 
2 weeks, because of toxicity of preoperative chemo-
therapy—grade 4 neutro penia. For all 24 weeks of 
chemotherapy, 49% of patients (47 of 95) in the preoperative 
chemotherapy group and 51% of patients (20 of 39) in the 
postoperative group had any grade 3 or higher adverse 
events, with the most common being haematological (29% 
[28 of 95] and 28% [11 of 39]) and gastrointestinal (19% 
[18 of 95] and 21% [eight of 39]) adverse events (appendix).
Signiﬁ cant diﬀ erences favouring preoperative therapy 
were seen in apical node involvement in the resected 
specimens (one of 98 vs ten of 50; p<0·0001), TNM5 
staging (p=0·04), resection margin involvement (four of 
99 vs ten of 50; p=0·002), and retroperitoneal margin 
involvement (ﬁ ve of 94 vs eight of 44; p=0·016; table 3). 
Preoperative plus 
postoperative 
chemotherapy(n=99)
Postoperative 
chemotherapy 
only (n=51)
p value
Anastomotic leak 5 (5%) 2 (4%) 0·77
Wound infection with or without intra-abdominal 
abscess*
13 (13%) 4 (8%) 0·34
Bronchopneumonia 2 (2%) 0 0·31
Deep vein thrombosis 2 (2%) 0 0·31
Rash 3 (3%) 0 0·21
Neutropenia 1 (1%) 0 0·47
Death 0 1 (2%) 0·16
Other 12 (12%) 6 (12%) 0·72
Complication prolonging hospital stay 14 (14%) 6 (12%) 0·81
Procedure resulting in a stoma 12 (12%) 5 (10%) 0·66
Further abdominal surgery needed 4 (4%) 2 (4%) 0·96
*All three patients with intra-abdominal abscess also had wound infection recorded.
Table 2: Perioperative complications in the preoperative plus postoperative chemotherapy group 
compared with the postoperative chemotherapy group
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31% of (29 of 94) tumours in the pre operative group with 
blinded centrally scored regression grades showed 
moderate to complete regression as compared with 2% 
(one of 46) in the control series (p=0·0001). There were 
reductions in tumour diameter, tumour thickness, and 
depth of spread beyond the muscularis propria in the 
preoperative group compared with controls. There were 
two complete pathological responses and seven T2 
tumours in the preoperative group, with only one T2 
tumour in the control group. However, downstaging as 
Preoperative and post-
operative chemotherapy 
group (n=99)
Postoperative 
chemotherapy only 
group (n=50)* 
p value
Resection margins
R0–complete 95 (96%) 40 (80%) 0·002
R1–incomplete/R2 4 (4%) 10 (20%) ··
Mean distance to nearer margin (mm) 68·4 (56·6); n=97 70·9 (59·9); n=46 0·81
Maximum tumour thickness (mm) 18·5 (12·1); n=61 24·4 (16·7); n=33 0·08
Maximum tumour diameter (mm) 49·6 (45·4); n=93 62·2 (28·0); n=46 0·05
Distance to retroperitoneal margin (mm) 20·7 (16·1); n=65 19·7 (25·6); n=32 0·85
Maximum spread beyond muscularis propria (mm) 6·9 (6·4); n=89 8·7 (7·4); n=43 0·14
T stage TNM5
T0 (no tumour) 2 0 MH=0·16; MH combining T0/1/2 and T4=0·20
T1 (invades submucosa) 0 0 ··
T2 (invades muscularis propria) 7 1 ··
T3 (invades through muscularis propria) 60 30 ··
T4 (penetrates to peritoneum) 17 11 ··
T4 (invades adjacent organs) 13 8 ··
N stage TNM5
Nx 1 0 ··
N0 59 24 MH=0·039
N1 (1–3 nodes) 24 10 ··
N2 (≥4 nodes) 15 16 ··
Lymph nodes examined
0–5 2 0 MH=0·25
6–11 6 2 ··
12–20 40 16 ··
21–30 33 19 ··
31–40 12 8 ··
≥40 6 3 ··
Median 21 (15–27) 22 (16–30) 0·20
Apical nodes positive 1/98 10/50 <0·0001
Extramural vascular invasion 34/97 24/48 0·085
American (TNM5) staging
No tumour 2 0 MH=0·04
Stage 1 6 1 ··
Stage 2 (low risk) 17 6 ··
Stage 2 (high risk†) 35 17 ··
Stage 3 38 24 ··
Stage 4 1 2 ··
Tumour regression grading
Complete response 2 0 MH=0·0004; any vs little/no regression MH=0·0001
Marked regression 2 0 ··
Moderate regression 25 1 ··
Little/no regression 65 45 ··
Data are n (%), mean (SD), or median (IQR). *The two extra tumours are the two that were unresected. Macroscopic evaluation was used. †Either T4, T3 with extramural 
vascular invasion, or T3 with ≥5 mm invasion of the muscularis propria. MH=Mantel-Haenszel test, TNM5=American Joint Committee on Cancer, ﬁ fth edn. 
Table 3: Tumour characteristics on pathological examination
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assessed by T stage was not signiﬁ cant (table 3). The 
proportion of tumours with involved lymph nodes was 
lower (40% [39 of 98] vs 52% [26 of 50], test for association 
p=0·039) in the preoperative chemotherapy group, with 
the number of lymph nodes identiﬁ ed for histology 
assessment being similar between groups.
55%  (11 of 20) of the tumours apparently downstaged 
between initial radiological assessment and pathological 
examination were also downstaged on radiology assess-
ment after preoperative chemotherapy. None were 
upstaged. Conversely, 35% (six of 17) of the tumours 
apparently upstaged between initial radiological assess-
ment and pathological examination were also upstaged 
on post chemotherapy radiology. None were downstaged. 
Reductions in the mean depth of spread beyond the 
muscularis propria (12·8 [SD 8·4] to 9·0 [7·9] mm; 
p=0·0022) and in the maximum tumour thickness 
(24·9 [12·2] to 19·0 [12·8] mm; p=0·0018) were also 
seen in the second radiological assessment com pared 
with baseline.
Discussion
FOxTROT is, to our knowledge, the ﬁ rst randomised trial 
to evaluate preoperative chemotherapy in primary colon 
cancer (panel). The pilot phase has provided clear evidence 
of downstaging with only 6 weeks of pre operative 
treatment. The signiﬁ cant reductions in apical node 
involvement, incomplete resections, and two pathological 
complete responses, are note worthy since all have 
previously been shown to correlate with protracted disease-
free survival.11 Tumour regres sion grading after preoperative 
chemotherapy also correlates with recurrence risk in other 
gastointestinal malignancies,33 and longer follow-up of the 
FOxTROT cohort should establish whether tumour 
regression grading is similarly prognostic in colon cancer.
We have also shown that preoperative therapy is 
practicable and safe with no increase in surgical morbidity 
or mortality—a major focus of the feasibility study. With a 
3-week delay after chemotherapy, surgery can be completed 
within 10 weeks from diagnosis. A small proportion (17%) 
of patients in the preoperative chemo therapy group had 
apparent progression between diagnostic radiology and 
post-resection pathology but, reassuringly, no patients 
developed incipient obstruction during the 6-week 
preoperative chemotherapy. A central review of CT scans is 
being undertaken to investigate whether the apparent 
upstaging was due to inaccurate initial radiological staging 
or true progression and will be reported separately. The 
absence of measurable adverse eﬀ ects in terms of 
prolonged hospital stay, stoma for mation, reoperation 
rates, and leak rates is, again, encouraging. A trend 
towards increased wound and chest infection was expected 
and seen, but was not signiﬁ cant. Compliance with 
postoperative chemo therapy, a potential surrogate marker 
for surgical morbidity, was not reduced in the preoperative 
group. Diarrhoea and skin rash were lower than previously 
reported with combination oxaliplatin, ﬂ uoropyrimidine, 
and EGFR antibody therapy,17 probably because only 31% 
received panitumumab—the panitumumab comparison 
is still masked—and also because of the short (6-week) 
duration preoperative treatment.
Another key ﬁ nding is that a high-risk cohort suitable 
for combination chemotherapy can be identiﬁ ed by 
radiological assessment across multiple sites. The risk of 
exposing patients with early stage (pT2) disease to 
inappropriate chemotherapy was low, with only one 
patient of 51 (2%) being inaccurately upstaged, justifying 
the ongoing phase 3 trial. Chemotherapy for the 12% with 
pT3 tumours without additional risk factors is not 
unreasonable in view of the established eﬃ  cacy of 
chemotherapy in stage 2 disease.34 In a parallel audit,35 
93% of patients with radiologically staged T3 tumours 
with less than 5 mm invasion of the muscularis propria 
were found to have coexisting high-risk pathological 
features that justify chemotherapy and the eligibility 
criteria for the full FOxTROT study have been amended 
accordingly. As radiological staging of primary colon 
cancer is underdeveloped, a series of workshops—
attended by 200 gastrointestinal radiologists—were held 
to standardise radiological selection criteria and similar 
training would be advisable in other neoadjuvant trials.
The population studied in FOxTROT seemed typical of 
those who might be considered for neoadjuvant therapy. 
The median age of 63 years is 10 years younger than the 
colon cancer population as a whole, but typical for trials 
of adjuvant chemotherapy. The distribution of tumours 
in the study largely reﬂ ects that of colonic tumours in the 
population, other than fewer tumours from the recto-
sigmoid region, probably because of consideration for 
radiotherapy, an exclusion criterion. The fairly high 
(20%) resection margin involvement in control patients 
is probably explained by more rigorous histopathological 
assessment and by selection of high-risk patients.
Delivery of KRAS mutation analysis across 35 UK 
sites was another challenge, since delay in treatment 
would preclude clinical use. Our 9-day median time 
from consent to KRAS testing to randomisation for 
Panel: Research in context
Systematic review
We searched Medline and Embase for the MeSH and free terms: “colon” or “colonic“ near 
“cancer”, “carcinoma”, “tumor”, “tumour”, or “neoplasm” and drug therapy or chemotherapy 
and neoadjuvant or preoperative combined with appropriate study design ﬁ lter as described 
in section 6.4.11 of The Cochrane Handbook of Systematic Reviews of Interventions. No date or 
language restrictions were applied. No randomised trials comparing preoperative systemic 
chemotherapy with no chemotherapy in operable colon cancer were identiﬁ ed.
Interpretation
6 weeks of preoperative OxMdG chemotherapy for radiologically staged, locally advanced 
operable primary colon cancer is feasible with acceptable toxicity and perioperative 
morbidity and is associated with a signiﬁ cant pathological response. Further investigation 
of neoadjuvant chemotherapy of colon cancer is needed to evaluate long-term 
oncological outcome.
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panitumumab was achieved with a two-stage consent 
process and, importantly, a histopathology principal 
investigator at every site who helped to ensure that the 
biopsy sample was released for analysis promptly. Another 
concern that testing of small biopsies would be inaccurate 
also proved unfounded, with an assay failure rate of only 
4%, and the concordance between KRAS mutation assays 
of matched samples from the multiple biopsies and 
resected tumour was 99%,36 showing the reliability of 
DNA-based assays of colon cancer biopsies.
A particular strength of neoadjuvant over metastatic 
studies is that pre-treatment and post-treatment tissue 
samples are available to assess markers of tumour 
response. If validated as a surrogate of long-term 
oncological outcome, regression grading provides the 
most statistically sensitive measure of chemosensitivity to 
allow identiﬁ cation of predictive molecular markers and, 
potentially, to guide postoperative adjuvant treat ment. 
Radio logical assessment after preoperative therapy pro-
vided supportive evidence for real downstaging and could 
also be useful in assessment of primary tumour response 
and the potential value of extending pre operative therapy.
In summary, we have shown that patients with 
locally advanced, but resectable, colon cancer can be 
appropriately selected for neoadjuvant chemotherapy with 
CT scanning, can be molecularly stratiﬁ ed preoperatively, 
and can safely undergo preoperative chemotherapy 
followed by colonic resectional surgery, without incurring 
signiﬁ cant perioperative morbidity. We have also shown 
signiﬁ cant downstaging of primary tumours, including 
fewer incomplete resections and reduced apical lymph 
node metastases, after only 6 weeks of combination 
therapy. On the basis of these promising ﬁ ndings from the 
pilot phase, proceeding to the ongoing FOxTROT phase 3 
study is appropriate; we aim to enrol at least a further 
900 patients. If preoperative therapy results in fewer 
recurrences, as well as tumour downstaging, the esta-
blished pathway of surgery then chemotherapy in the 
management of colon cancer could potentially change.
FOxTROT Collaborative Group
Writing committee: UK Dion Morton (University Hospital Birmingham, 
Birmingham); Matt Seymour (St James’s University Hospital, Leeds); 
Laura Magill, Kelly Handley (University of Birmingham Clinical Trials 
Unit, Birmingham); Gina Brown (Royal Marsden Hospital, London); 
David Ferry (Russell’s Hall Hospital, Dudley); Nick West, Philip 
Quirke (Pathology and Tumour Biology, Leeds Institute of Molecular 
Medicine, University of Leeds, Leeds); Bryan Warren† (John Radcliﬀ e 
Hospital, Oxford); Richard Gray (Clinical Trial Service Unit, University 
of Oxford, Oxford).
†Deceased March, 2012
Contributors
FOxTROT trial was designed by DM, RG, MS, LM, GB, DF, PQ, and 
BW. Analyses were undertaken by KH, RG, DM, and LM. NW and PQ 
undertook central pathological review. DM and RG drafted the report 
and revised it with input from all writing committee members.
Conﬂicts of interest
We declare that we have no conﬂ icts of interest. 
Data Monitoring Committee
T Crosby, J Olliﬀ , R Peto (Chair).
Trial Management Committee
G Brown, D Ferry, R Gray, K Handley, T Ismail, L Magill, D Morton, 
A Oliver, P Quirke, M Seymour, N Scott, I Swift, B Warren.
Trial Steering Committee
J Northover, M Parmar, M Slevin (Chair).
The following centres and investigators (listed in alphabetical order) 
participated in the trial: (the principal investigator at each centre is 
indicated by *)
Arrowe Park Hospital D A Agbamu, N Day*, C J Walsh; Birmingham 
Heartlands Hospital I Geh, C W Hendrickse*, G Langman, A Pallan; 
Bradford Royal Inﬁ rmary A Conn*, A Lowe, J Ostrowski, M Steward; Bristol 
Royal Inﬁ rmary M Callaway, S Falk, M G Thomas*, N Wong; Castle Hill 
Hospital J Cast, J Hartley, A W MacDonald; Charing Cross Hospital D Blunt, 
P Cohen, P Dawson, C P Lowdell*; Chesterﬁ eld Royal Hospital H Euinton, 
D Furniss*, R Gupta, D Taraporewalla; Christie Hospital M Braun*; City 
Hospital Birmingham N Cruickshank*, S Muzaﬀ ar; Clatterbridge Centre For 
Oncology D Smith*; Derriford Hospital C Adams*, F Daniel, J Denson, 
S Jackson, K Sleigh; Diana, Princess Of Wales Hospital E Kweka, 
H J Pearson, M Peters, R Roy*; Doncaster Royal Inﬁ rmary G Kurien, 
J Robinson, J Wadsley*, D White; Dorset County Hospital M J Lamparelli, 
J Mikel, R Osborne*, P Taylor; Hampshire Hospitals NHS Foundation Trust 
I C Ilesley, B J Moran, H O’Neill, C Rees*; Harrogate District Hospital 
A Buxton, J Harrison, K Last*, D Scullion; Huddersﬁ eld Royal Inﬁ rmary 
J Dent*, J Hyde, D Ilsley, U Raja, C Roberts; Ipswich Hospital M Crabtree, 
J Orrell, S Smith, R Soomal*; Manchester Royal Inﬁ rmary J Hill*, 
G Howarth, S Lee; Manor Hospital R Church, A Hartley*, C Holland, 
A K Thompson; Mount Vernon Hospital R Glynne-Jones*, J Livingstone, 
P Richman, M Train; Musgrove Park Hospital C Barlow, P Burn, J Geraghty, 
C J Vickery, J Walther*; New Cross Hospital S Grumett*, S A M Mangalika, 
M Qaiyum, G Williams; North Middlesex Hospital R Borgstein, 
J A Bridgewater*, L Meleagros, J A Rees, S J Needham, J Scott; Pinderﬁ elds 
General Hospital A Anathhanam, J Brittenden, C Macklin, D Swinson*; 
Poole General Hospital J Alexander, T F G Hickish*, R W Talbot, D Tarver; 
Princess Alexandra Hospital J A Bridgewater*, O Lalude, W Partridge, 
V Sundaresan; Queen Alexandra Hospital D Cowlishaw, A Higginson, 
S R Muthuramalingam*, D P O’Leary; Queen Elizabeth Hospital 
Birmingham T Ismail, D G Morton, A Page, N Steven*, P Taniere; Queen’s 
Hospital, Romford J Gutmann, J Huang, S Raouf*, I T Saeed; Queens 
Medical Centre W K Dunn, V Potter*, J H Scholeﬁ eld, A Zaitoun; Raigmore 
Hospital D Eason, G Stenhouse, K G Walker, A J Watson, D Whillis*; Royal 
Bournemouth General Hospital B Fozard, T F G Hickish*, J McCutcheon, 
S Snape; Royal Cornwall Hospital (Treliske) R Ellis*, W Faux, G Maskell, 
J Mathew; Royal Free Hospital J R G Bell, A Mayer*, O A Ogunbiyi, 
J Watkins; Royal Lancaster Inﬁ rmary C Bronder, D Eaton*, N Mapstone, 
A Taylor; Royal Marsden Hospital G Brown, D Cunningham*, P Tekkis, 
A Wotherspoon; Royal Preston Hospital D Barber, M Dobson, M Pitt, 
N Scot*, S Susnerwala; Russells Hall Hospital D Ferry*, A Hall, A Kawesha, 
A Sherif; Salford Royal Hospital H Burnett, S Hayes, N Lees*; Salisbury 
District Hospital G Branagan, S Cook, C Fuller, T Iveson*; Sandwell General 
Hospital N Cruickshank*, R Donovan, S Muzaﬀ ar, D Peake; Scunthorpe 
General Hospital S Ahmad, A Coup, A Hamid*, D Pai; Southampton General 
Hospital A C Bateman*, A R Bateman, R M Blaquiere, P Nichols; Southend 
Hospital M J Dworkin, S Jain, A Malhotra, B Pravee, D Tsang*; Southmead 
& Frenchay Hospitals K Hopkins*, E Loveday, A Pullyblank, N Rooney; 
Southport & Formby District General Hospital A Chiphang, S Dundas, 
A S Myint*, M Zeiderman; St George’s Hospital N Beharry, C Finlayson, 
R Hagger, F Lofts*, D M Melville; St James’s University Hospital P J Finan, 
N Scott, M Seymour*, D Tolan; Stepping Hill Hospital J Hasan*, V Howarth, 
S Mehta, M Saeed; The Royal Liverpool University Hospital F Campbell, 
M L Hughes, P Rooney*, D Smith; University Hospital Of North Staﬀ ordshire 
F Adab*, I Britton, C Hall, C Phelan; Warrington & Halton Hospitals 
A Moss*, N Pranesh, D Shareef, J Whalley; West Middlesex University 
Hospital R Ahmad*, S Desai, S Ramesh, C Ramsey; Weston Park Hospital 
S Amin, J Hampton, J Hornbuckle*, P Kitsanta; Wexham Park Hospital 
M Charig, A L Desai, M Hall*, M Thyveetil; Worcester Royal Inﬁ rmary 
A Baxter, D Farrugia*, S P Lake, T Roberts, G T Smith; Wrexham Maelor 
Hospital T Burdge, P Chandran, C Corr, S Gollins*; Wythenshawe Hospital 
M Braun*, S Pritchard, M Scott, S Sukumar; York Hospital A Clarke, 
J Haselden, K Last*, N Woodcock; Ysbyty Glan Clwyd M W Atkinson, 
S Gollins*, M Gupta, A Maw; Ysbyty Gwynedd Day Hospital C Bale*, E Favill.
Articles
1160 www.thelancet.com/oncology   Vol 13   November 2012
Acknowledgments
FOxTROT is funded by Cancer Research UK. Panitumumab was provided 
free of charge by Amgen, who also supported KRAS testing and additional 
CT scans. PQ and NW are supported by Yorkshire Cancer Research, RG 
by the Medical Research Council. Additional support was provided by the 
ECMC network. We thank the patients and clinicians who have supported 
the trial. This paper is dedicated to the memory of Prof Bryan Warren, 
gastrointestinal pathologist, who died in March, 2012, at the age of 53.
“Bryan was hugely admired for his intelligence, his dynamism, and
his extraordinary sense of fun both in the UK and internationally. We have 
lost a great friend, a loyal colleague, and a supreme intellect.”37
References
1 Medical Research Council Oesophageal Cancer Working Party. Surgical 
resection with or without preoperative chemotherapy in oesophageal 
cancer: a randomised controlled trial. Lancet 2002; 359: 1727–33.
2 Cunningham D, Allum WH, Stenning SP, et al, for the MAGIC Trial 
Participants. Perioperative chemotherapy versus surgery alone for 
resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.
3 Sebag-Monteﬁ ore D, Stephens RJ, Steele D, et al. Preoperative 
radiotherapy versus selective postoperative chemoradiotherapy in 
patients with rectal cancer (MRC CR07 and NCIC-CTG C016): 
a multicentre, randomised trial. Lancet 2009; 373: 811–20.
4 Finlay IG, Meek D, Brunton F, McArdle CS. Growth rate of hepatic 
metastases in colorectal carcinoma. Br J Surg 1988; 75: 641–44.
5 Tanaka K, Shimada H, Miura M, et al. Metastatic tumor doubling 
time: most important pre-hepatectomy predictor of survival and 
non-recurrence of hepatic colorectal cancer metastasis. World J Surg 
2004; 28: 263–70.
6 Zeamari S, Roos E, Stewart FA. Tumour seeding in peritoneal 
wound sites in relation to growth-factor expression in early 
granulation tissue. Eur J Cancer 2004; 40: 1431–40.
7 Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. 
Transcription factor Egr-1 supports FGF-dependent angiogenesis 
during neovascularization and tumor growth. Nat Med 2003; 
9: 1026–32.
8 Schelfhout VR, Coene ED, Delaey B, et al. The role of 
heregulin-alpha as a motility factor and amphiregulin as a growth 
factor in wound healing. J Pathol 2002; 198: 523–33.
9 Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and 
rectal cancer surgery. J Natl Cancer Inst 2001; 93: 583–96.
10 Kapiteijn E, Marijnen CA, Nagtegaal ED, et al. Preoperative 
radiotherapy combined with total mesorectal excision for resectable 
rectal cancer. N Engl J Med 2001; 345: 638–46.
11 Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of 
rectal adenocarcinoma due to inadequate surgical resection. 
Histopathological study of lateral tumour spread and surgical 
excision. Lancet 1986; 2: 996–99.
12 Nomura K, Miyagawa S, Harada H, et al. Relationship between 
doubling time of liver metastases from colorectal carcinoma and 
residual primary cancer. Dig Surg 1998; 15: 21–24.
13 Assersohn L, Norman A, Cunningham D, et al. Inﬂ uence of 
metastatic site as an additional predictor for response and outcome 
in advanced colorectal carcinoma. Br J Cancer 1999; 79: 1800–05.
14 Guillou PJ, Quirke P, Thorpe H, et al, MRC CLASICC trial group. 
Short-term endpoints of conventional versus laparoscopic-assisted 
surgery in patients with colorectal cancer (MRC CLASICC trial). 
Lancet 2005; 365: 1718–26.
15 Smith NJ, Bees N, Barbachano Y, et al. Pre-operative computed 
tomography staging of non-metastatic colon cancer predicts outcome: 
implications for clinical trials. Br J Cancer 2007; 96: 1030–36.
16 Seymour MT, Maughan TS, Ledermann JA, et al, for the FOCUS 
Trial Investigators. Diﬀ erent strategies of sequential and 
combination chemotherapy for patients with poor prognosis 
advanced colorectal cancer (MRC FOCUS): a randomised controlled 
trial. Lancet 2007; 370: 143–52.
17 Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to 
oxaliplatin-based ﬁ rst-line combination chemotherapy for treatment 
of advanced colorectal cancer: results of the MRC COIN trial. Lancet 
2011; 377: 2103–14.
18 Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations 
and beneﬁ t from cetuximab in advanced colorectal cancer. 
N Engl J Med 2008; 359: 1757–65.
19 Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required 
for panitumumab eﬃ  cacy in patients with metastatic colorectal 
cancer. J Clin Oncol 2008; 26: 1626–34.
20 Panitumumab Summary of Product Characteristics, Amgen, 
June 9, 2011. http://www.emea.europa.eu/ (accessed Sept 12, 2012).
21 Peeters M, Price CJ, Cervantes A, et al. Randomized phase III study 
of panitumumab with ﬂ uorouracil, leucovorin, and irinotecan 
(FOLFIRI) compared with FOLFIRI alone as second-line treatment 
in patients with metastatic colorectal cancer. J Clin Oncol 2010; 
28: 4706–13. 
22 Seymour M, Brown S, Richman S, et al. PICCOLO—a large 
multicentre trial with molecular stratiﬁ cation in chemoresistant 
advanced colorectal cancer: evaluation of panitumumab in 
combination with irinotecan. 7th NCRI Cancer Conference, 
November 2011. http://www.ncri.org.uk/ncriconference/
2011abstracts/abstracts/PP30.html (accessed Sept 12, 2012).
23 Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of 
cetuximab plus irinotecan after ﬂ uoropyrimidine and oxaliplatin 
failure in patients with metastatic colorectal cancer. J Clin Oncol 
2008; 26: 2311–19. 
24 Van Cutsem E, Kohne C-H, Hitre E, et al. Cetuximab and 
chemotherapy as initial treatment of metastatic colorectal cancer. 
N Engl J Med 2009; 360: 1408–17.
25 Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, 
leucovorin, and oxaliplatin with and without cetuximab in the ﬁ rst-line 
treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663–71.
26 Douillard J-Y, Siena S, Cassidy J, et al. Randomized phase III trial of 
panitumumab with FOLFOX4 vs FOLFOX4 alone as ﬁ rst-line 
treatment in metastatic colorectal cancer: the PRIME study. 
J Clin Oncol 2010; 28: 4697–705. 
27 Hecht JR, Mitchell E, Chidiac T, et al. Randomized phase IIIB trial 
of chemotherapy, bevacizumab, and panitumumab compared with 
chemotherapy and bevacizumab alone for metastatic colorectal 
cancer. J Clin Oncol 2009; 27: 672–80.
28 Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab and 
cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 
360: 563–72. 
29 Borner M, Koeberle D, Von Moos R, et al, for the Swiss Group for 
Clinical Cancer Research (SAKK). Adding cetuximab to capecitabine 
plus oxaliplatin (XELOX) in ﬁ rst-line treatment of metastatic 
colorectal cancer: a randomized phase II trial of the Swiss Group 
for Clinical Cancer Research (SAKK). Ann Oncol 2008; 19: 1288–92.
30 Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab 
with continuous or intermittent ﬂ uorouracil, leucovorin, and 
oxaliplatin (Nordic FLOX) versus FLOX alone in ﬁ rst-line treatment 
of metastatic colorectal cancer: the NORDIC-VII Study. J Clin Oncol 
2012; 30: 1755–62. 
31 Moosmann N, Fischer von Weikersthal L, Vehling-Kaiser U, et al. 
Cetuximab plus capecitabine and irinotecan compared with 
cetuximab plus capecitabine and oxaliplatin as ﬁ rst-line treatment 
for patients with metastatic colorectal cancer: AIO KRK-0104— 
a randomized trial of the German AIO CRC Study Group. 
J Clin Oncol 2011; 29: 1050–58.
32 Cheeseman SL, Joel S, Chester JD, et al. A “modiﬁ ed de Gramont” 
regimen of ﬂ uorouracil, alone (MdG) and with oxaliplatin (OxMdG), 
for advanced colorectal cancer. Br J Cancer 2002; 87: 393–99.
33 Rödel C, Martus P, Papadoupolos T, et al. Prognostic signiﬁ cance of 
tumor regression after preoperative chemoradiotherapy for rectal 
cancer. J Clin Oncol 2005; 23: 8688–96. 
34 QUASAR Collaborative Group. Adjuvant chemotherapy versus 
observation in patients with colorectal cancer: a randomised study. 
Lancet 2007; 370: 2020–29.
35 Dighe S, Swift I, Magill L, et al. Accuracy of radiological staging in 
identifying high-risk colon cancer patients suitable for neoadjuvant 
chemotherapy: a multicentre experience. Colorectal Dis 2011; 14: 438–44.
36 West N, Hemmings G, Richman S, et al. Can KRAS and BRAF 
mutational status be accurately determined on diagnostic tissue 
biopsies from patients with colon cancer? An analysis of matched 
biopsy and resection material from the NCRI FOxTROT trial. NCRI 
Conference 2011. http://www.ncri.org.uk/ncriconference/
2011abstracts/abstracts/PP36.html (accessed Sept 12, 2012).
37 Shepherd NA, Novelli MR, Williams GT. Professor Bryan F 
Warren—obituary. Histopathology 2012, 61: 138–39.
